Neprilysin inhibitors provide insight into its specificity and therapeutic potential

Drug Design and Discovery in Alzheimer's Disease

Volumn , Issue , 2014, Pages 598-622

  Pope, Darrick ^a   Cascio, Michael ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Computational modeling; Metallopeptidases; Neprilysin; Neurodegeneration; Proteolysis; Substrate binding; Zinc dependent endopeptidase

Indexed keywords

ENZYMES; GLYCOPROTEINS; PEPTIDES; PROTEOLYSIS;

ALZHEIMER'S DISEASE; AMYLOID-BETA PEPTIDES; COMPUTATIONAL MODEL; METALLOPEPTIDASES; NEPRILYSIN; NEURODEGENERATION; SUBSTRATE BINDING;

NEURODEGENERATIVE DISEASES;

EID: 84940864344     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-803959-5.50013-1     Document Type: Chapter

References (75)

1. Turner, A.J., R.E. Isaac, and D. Coates. The neprilysin (NEP) family of zinc metalloendopeptidases:genomics and function. Bioessays, 2001, 23(3), 261-9.
2. Turner, A.J. and K. Tanzawa. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J, 1997, 11(5), 355-64.
3. Roques, B.P., F. Noble, V. Dauge, M.C. Fournie-Zaluski, and A. Beaumont. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev, 1993, 45(1), 87-146.
4. Iijima-Ando, K., S.A. Hearn, L. Granger, C. Shenton, A. Gatt, H.C. Chiang, I. Hakker, Y. Zhong, and K. Iijima. Overexpression of neprilysin reduces Alzheimer amyloid-beta 42 (A beta 42)-induced neuron loss and intraneuronal A beta 42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. Journal of Biological Chemistry, 2008, 283(27), 19066-19076.
5. Barnes, K., A.J. Turner, and A.J. Kenny. An immunoelectron microscopic study of pig substantia nigra shows co-localization of endopeptidase-24.11 with substance P. Neuroscience, 1993, 53(4), 1073-82.
6. Malfroy, B., J.P. Swerts, A. Guyon, B.P. Roques, and J.C. Schwartz. High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature, 1978, 276(5687), 523-6.
7. Matsas, R., I.S. Fulcher, A.J. Kenny, and A.J. Turner. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci U S A, 1983, 80(10), 3111-5.
8. Schwartz, J.C., S. de la Baume, B. Malfroy, G. Patey, R. Perdrisot, J.P. Swerts, M.C. Fournie-Zaluski, G. Gacel, and B.P. Roques. "Enkephalinase", a newly characterised dipeptidyl carboxypeptidase: properties and possible role in enkephalinergic transmission. Int J Neurol, 1980, 14(2-4), 195-204.
9. Oefner, C., B.P. Roques, M.C. Fournie-Zaluski, and G.E. Dale. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallographica Section DBiological Crystallography, 2004, 60(Journal Article), 392-396.
10. Chemical Computing Group, I., Molecular Operating Environment. 2011, Chemical Computing Group Inc.: Montreal, QC, Canada, H3A 2R7. p. Molecular Visualization and Simulation Program.
11. Hooper, N.M. Families of zinc metalloproteases. FEBS Lett, 1994, 354(1), 1-6.
12. Cummins, P.M., A. Pabon, E.H. Margulies, and M.J. Glucksman. Zinc coordination and substrate catalysis within the neuropeptide processing enzyme endopeptidase EC 3.4.24.15. Identification of active site histidine and glutamate residues. J Biol Chem, 1999, 274(23), 16003-9.
13. Oefner, C., A. D'Arcy, M. Hennig, F.K. Winkler, and G.E. Dale. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol, 2000, 296(2), 341-9.
14. Oefner, C., S. Pierau, H. Schulz, and G.E. Dale. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Acta Crystallogr D Biol Crystallogr, 2007, 63(Pt 9), 975-81.
15. Dale, G.E. and C. Oefner, Neprilysin, in Handbook of Metalloproteins. 2006, John Wiley & Sons, Ltd.
16. Weaver, L.H., W.R. Kester, and B.W. Matthews. A crystallographic study of the complex of phosphoramidon with thermolysin. A model for the presumed catalytic transition state and for the binding of extended substances. J Mol Biol, 1977, 114(1), 119-32.
17. Kester, W.R. and B.W. Matthews. Crystallographic study of the binding of dipeptide inhibitors to thermolysin: implications for the mechanism of catalysis. Biochemistry, 1977, 16(11), 2506-16.
18. Leissring, M.A., A. Lu, M.M. Condron, D.B. Teplow, R.L. Stein, W. Farris, and D.J. Selkoe. Kinetics of amyloid beta-protein degradation determined by novel fluorescenceand fluorescence polarization-based assays. J Biol Chem, 2003, 278(39), 37314-20.
19. Tiraboschi, G., N. Jullian, V. Thery, S. Antonczak, M.C. Fournie-Zaluski, and B.P. Roques. A three-dimensional construction of the active site (region 507-749) of human neutral endopeptidase (EC.3.4.24.11). Protein Eng, 1999, 12(2), 141-9.
20. Chen, H., F. Noble, A. Mothe, H. Meudal, P. Coric, S. Danascimento, B.P. Roques, P. George, and M.C. Fournie-Zaluski. Phosphinic derivatives as new dual enkephalindegrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities. J Med Chem, 2000, 43(7), 1398-408.
21. Beaumont, A., H. Le Moual, G. Boileau, P. Crine, and B.P. Roques. Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (EC 3.4.24.11). J Biol Chem, 1991, 266(1), 214-20.
22. Kim, Y.A., B. Shriver, T. Quay, and L.B. Hersh. Analysis of the importance of arginine 102 in neutral endopeptidase (enkephalinase) catalysis. J Biol Chem, 1992, 267(17), 12330-5.
23. Marie-Claire, C., E. Ruffet, S. Antonczak, A. Beaumont, M. O'Donohue, B.P. Roques, and M.C. Fournie-Zaluski. Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding. Biochemistry, 1997, 36(45), 13938-45.
24. Roderick, S.L. and B.W. Matthews. Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: a new type of proteolytic enzyme. Biochemistry, 1993, 32(15), 3907-12.
25. Dion, N., H. Le Moual, M.C. Fournie-Zaluski, B.P. Roques, P. Crine, and G. Boileau. Evidence that Asn542 of neprilysin (EC 3.4.24.11) is involved in binding of the P2' residue of substrates and inhibitors. Biochem J, 1995, 311 ( Pt 2), 623-7.
26. Manzetti, S., D.R. McCulloch, A.C. Herington, and D. van der Spoel. Modeling of enzymesubstrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10. J Comput Aided Mol Des, 2003, 17(9), 551-65.
27. Manzetti, S. Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases. J Mol Model, 2003, 9(5), 348-54.
28. Dimitropoulos, N., A. Papakyriakou, G.A. Dalkas, E.D. Sturrock, and G.A. Spyroulias. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors. J Chem Inf Model, 2010, 50(3), 388-96.
29. Burrell, L.M., N.K. Farina, L.C. Balding, and C.I. Johnston. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension, 2000, 36(6), 1105-11.
30. Hardy, J. and D.J. Selkoe. Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
31. Mawuenyega, K.G., W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J.C. Morris, K.E. Yarasheski, and R.J. Bateman. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science, 2010, 330(6012), 1774.
32. Miners, J.S., N. Barua, P.G. Kehoe, S. Gill, and S. Love. Abeta-degrading enzymes:potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol, 2011, 70(11), 944-59.
33. Citron, M. Alzheimer's disease: strategies for disease modification. Nature Reviews Drug Discovery, 2010, 9(5), 387-398.
34. Weiner, H.L. and D. Frenkel. Immunology and immunotherapy of Alzheimer's disease (vol 6, pg 404, 2006). Nature Reviews Immunology, 2006, 6(6), 490-490.
35. De Strooper, B. Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. Physiological Reviews, 2010, 90(2), 465-494.
36. Carare, R.O., C.A. Hawkes, M. Jeffrey, R.N. Kalaria, and R.O. Weller. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol, 2013, 39(6), 593-611.
37. Miners, J.S., P. Kehoe, and S. Love. Neprilysin protects against cerebral amyloid angiopathy and Abeta-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol, 2011, 21(5), 594-605.
38. Hamley, I.W. The Amyloid Beta Peptide: A Chemist's Perspective. Role in Alzheimer's and Fibrillization. Chem Rev, 2012.
39. Serpell, L.C., C.C. Blake, and P.E. Fraser. Molecular structure of a fibrillar Alzheimer's A beta fragment. Biochemistry, 2000, 39(43), 13269-75.
40. Selkoe, D.J. and D. Schenk. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol, 2003, 43, 545-84.
41. Teplow, D.B. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid, 1998, 5(2), 121-42.
42. Ahmed, M., J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J.I. Elliott, W.E. Van Nostrand, and S.O. Smith. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nature Structural & Molecular Biology, 2010, 17(5), 561-U56.
43. Kelly, J.W. Towards an understanding of amyloidogenesis. Nature structural biology, 2002, 9(5), 323-325.
44. Goedert, M. and M.G. Spillantini. A century of Alzheimer's disease. Science, 2006, 314(5800), 777-81.
45. Dahlgren, K.N., A.M. Manelli, W.B. Stine, Jr., L.K. Baker, G.A. Krafft, and M.J. LaDu. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem, 2002, 277(35), 32046-53.
46. Maezawa, I., P. Zimin, H. Wulff, and L.-W. Jin. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. Journal of Biological Chemistry, 2011, 286(5), 3693-3706.
47. Ono, K., M.M. Condron, and D.B. Teplow. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(35), 14745-14750.
48. Hartley, D.M., D.M. Walsh, C.P. Ye, T. Diehl, S. Vasquez, P.M. Vassilev, D.B. Teplow, and D.J. Selkoe. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci, 1999, 19(20), 8876-84.
49. Zhang, Y., R. McLaughlin, C. Goodyer, and A. LeBlanc. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol, 2002, 156(3), 519-29.
50. Miners, J.S., Z. van Helmond, P.G. Kehoe, and S. Love. Changes with Age in the Activities of beta-Secretase and the A beta-Degrading Enzymes Neprilysin, Insulin-Degrading Enzyme and Angiotensin-Converting Enzyme. Brain Pathology, 2010, 20(4), 794-802.
51. Wang, S.Q., R. Wang, L. Chen, D.A. Bennett, D.W. Dickson, and D.S. Wang. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. Journal of neurochemistry, 2010, 115(1), 47-57.
52. Nalivaeva, N.N., L.R. Fisk, N.D. Belyaev, and A.J. Turner. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res, 2008, 5(2), 212-24.
53. Shirotani, K., S. Tsubuki, N. Iwata, Y. Takaki, W. Harigaya, K. Maruyama, S. Kiryu-Seo, H. Kiyama, H. Iwata, T. Tomita, T. Iwatsubo, and T.C. Saido. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem, 2001, 276(24), 21895-901.
54. Miners, J.S., S. Baig, J. Palmer, L.E. Palmer, P.G. Kehoe, and S. Love. A beta-degrading enzymes in Alzheimer's disease. Brain Pathology, 2008, 18(2), 240-252.
55. Iwata, N., S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N.P. Gerard, C. Gerard, E. Hama, H.J. Lee, and T.C. Saido. Metabolic regulation of brain A beta by neprilysin. Science, 2001, 292(5521), 1550-1552.
56. Iwata, N., S. Tsubuki, Y. Takaki, K. Watanabe, M. Sekiguchi, E. Hosoki, M. Kawashima-Morishima, H.J. Lee, E. Hama, Y. Sekine-Aizawa, and T.C. Saido. Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nature medicine, 2000, 6(2), 143-150.
57. Iwata, N., H. Mizukami, K. Shirotani, Y. Takaki, S. Muramatsu, B. Lu, N.P. Gerard, C. Gerard, K. Ozawa, and T.C. Saido. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. Journal of Neuroscience, 2004, 24(4), 991-998.
58. El-Amouri, S.S., H. Zhu, J. Yu, R. Marr, I.M. Verma, and M.S. Kindy. Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. American Journal of Pathology, 2008, 172(5), 1342-1354.
59. Miners, J.S., S. Morris, S. Love, and P.G. Kehoe. Accumulation of Insoluble Amyloid-beta in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities. Journal of Alzheimer's Disease, 2010 (1875-8908 (Electronic); 1387-2877 (Linking)).
60. Tampellini, D., N. Rahman, M.T. Lin, E. Capetillo-Zarate, and G.K. Gouras. Impaired beta-amyloid secretion in Alzheimer's disease pathogenesis. J Neurosci, 2011, 31(43), 15384-90.
61. Marr, R.A. and B.J. Spencer. NEP-like endopeptidases and Alzheimer's disease [corrected]. Curr Alzheimer Res, 2010, 7(3), 223-9.
62. Nalivaeva, N.N., C. Beckett, N.D. Belyaev, and A.J. Turner. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J Neurochem, 2012, 120 Suppl 1, 167-85.
63. Dubrovskaia, N.M., N.N. Nalivaeva, S.A. Plesneva, A.A. Feponova, A.J. Turner, and I.A. Zhuravin. [Changes in the activity of amyloid-degrading metallopeptidases leads to disruption of memory in rats]. Zh Vyssh Nerv Deiat Im I P Pavlova, 2009, 59(5), 630-8.
64. Nalivaeva, N.N., N.D. Belyaev, D.I. Lewis, A.R. Pickles, N.Z. Makova, D.I. Bagrova, N.M. Dubrovskaya, S.A. Plesneva, I.A. Zhuravin, and A.J. Turner. Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J Mol Neurosci, 2012, 46(3), 569-77.
65. Nalivaevaa, N.N., L. Fisk, E.G. Kochkina, S.A. Plesneva, I.A. Zhuravin, E. Babusikova, D. Dobrota, and A.J. Turner. Effect of hypoxia/ischemia and hypoxic preconditioning/ reperfusion on expression of some amyloid-degrading enzymes. Ann N Y Acad Sci, 2004, 1035, 21-33.
66. Marr, R.A., H. Guan, E. Rockenstein, M. Kindy, F.H. Gage, I. Verma, E. Masliah, and L.B. Hersh. Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci, 2004, 22(1-2), 5-11.
67. Hemming, M.L., M. Patterson, C. Reske-Nielsen, L. Lin, O. Isacson, and D.J. Selkoe. Reducing amyloid plaque burden via ex vivo gene delivery of an a beta-degrading protease:A novel therapeutic approach to Alzheimer Disease. Plos Medicine, 2007, 4(8), 1405-1416.
68. Li, Y., J. Wang, J. Liu, and F. Liu. A novel system for in vivo neprilysin gene delivery using a syringe electrode. J Neurosci Methods, 2010, 193(2), 226-31.
69. Guan, H., Y. Liu, A. Daily, S. Police, M.-H. Kim, S. Oddo, F.M. LaFerla, J.R. Pauly, M.P. Murphy, and L.B. Hersh. Peripherally Expressed Neprilysin Reduces Brain Amyloid Burden: A Novel Approach for Treating Alzheimer's Disease. Journal of neuroscience research, 2009, 87(6), 1462-1473.
70. Liu, Y., C. Studzinski, T. Beckett, H. Guan, M.A. Hersh, M.P. Murphy, R. Klein, and L.B. Hersh. Expression of Neprilysin in Skeletal Muscle Reduces Amyloid Burden in a Transgenic Mouse Model of Alzheimer Disease. Molecular Therapy, 2009, 17(8), 1381-1386.
71. Liu, Y., C. Studzinski, T. Beckett, M.P. Murphy, R.L. Klein, and L.B. Hersh. Circulating neprilysin clears brain amyloid. Molecular and Cellular Neuroscience, 2010, 45(2), 101-107.
72. Spencer, B., R.A. Marr, R. Gindi, R. Potkar, S. Michael, A. Adame, E. Rockenstein, I.M. Verma, and E. Masliah. Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces AB Toxicity in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2011, 6(1), 1-12.
73. Hersh, L.B. and D.W. Rodgers. Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res, 2008, 5(2), 225-31.
74. Howell, S., J. Nalbantoglu, and P. Crine. Neutral endopeptidase can hydrolyze betaamyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides, 1995, 16(4), 647-52.
75. Hashimoto, H., T. Takeuchi, K. Komatsu, K. Miyazaki, M. Sato, and S. Higashi. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of beta-amyloid precursor protein-derived inhibitor. J Biol Chem, 2011, 286(38), 33236-43.